Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 27, 2017
ORLANDO, Fla., Feb. 27, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted a novel approach to profiling immuno-oncology protein targets through digital quantification using the nCounter® Analysis System. The da...
Feb 24, 2017
SEATTLE, Feb. 24, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2016 financial results after the close of trading on Wednesday, March 1, 2017. Company m...
Feb 22, 2017
SEATTLE, Feb. 22, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston. Brad Gray, presid...
Feb 16, 2017
Hyb & Seq Single Molecule Chemistry Sequences Oncogenes from FFPE Samples with High Accuracy and Simple Workflow Free of Library, Enzymes and Amplification 3D Biology Enables Simultaneous Detection of Somatic DNA Mutations and Expressed Fusion Transcripts plus Expression Profiling of Proteins from Lung-Tumor FFPE Samples Digital Spatial Profi...
Jan 31, 2017
SEATTLE, Jan. 31, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Humana has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature Assay. Humana and its more than 13 million me...
Jan 10, 2017
SEATTLE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Blue Cross Blue Shield Association Evidence Street has issued a positive assessment of the Prosigna® Breast Cancer Gene Signature Assay...
Jan 10, 2017
- Expected Full Year 2016 Revenue Growth of 36% to 39% Year over Year - SEATTLE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today provided preliminary operational and financial results for the year ended Decemb...
Dec 22, 2016
SEATTLE, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the J.P. Morgan 35th Annual Healthcare Conference in San Francisco. Brad Gray, presid...
Dec 12, 2016
Prosigna Provides the Most Prognostic Information of Four Genomic Tests in Head-to-Head Comparison of Early Breast Cancer Node-Negative Patients Over a 10-Year Period SEATTLE, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic produ...
Dec 5, 2016
SEATTLE, Dec. 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced advances in precision oncology using the Prosigna® Breast Cancer Gene Signature Assay and the PAM50 gene signature, the basis for Prosigna, will...
Dec 1, 2016
SEATTLE, Dec. 01, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that its nCounter Vantage 3D™ assays, a portfolio of panels that enable simultaneous analysis of DNA, RNA, and protein were listed by The Scien...
Nov 30, 2016
SEATTLE, Nov. 30, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and hematology using the nCounter® platform that will be presented at the Annual Meeti...
Nov 11, 2016
In Special Recognition of the work of The Stand Up To Cancer-Lustgarten Foundation Pancreatic Dream Team and in honor of Pancreatic Cancer Awareness Month SEATTLE, Nov. 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today...
Nov 7, 2016
SEATTLE, Nov. 07, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, has begun accepting applications to a Technology Access Program (TAP) for its novel Digital Spatial Profiling technology (formerly referred to as digital IHC). In co...
Nov 2, 2016
SEATTLE, Nov. 02, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter ended September 30, 2016. Third Quarter Financial Highlights Total revenue of $23.9 million, 53% year-ov...
= add file to Briefcase